Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
37 Results for "
Lewy
" in MedChemExpress (MCE) Product Catalog:
Products (37)
37 Results for "Lewy" in MCE Product Catalog:
2
Target:
Research Areas:
Isocitric acid is an endogenous metabolite present in Saliva and Cellular_Cytoplasm that can be used for the research of Alzheimer's Disease, Lewy Body Dementia and Anoxia .
Target:
Cat. No.: HY-160116
CAS No.: 1565797-17-2
Research Areas:
α-Synuclein aggregate binder 1 (Compound C05-05) is a specific binder for α-synuclein aggregates and can inhibit α-synuclein aggregation. α-Synuclein aggregate binder 1 can be used as a fluorescent probe (excitation wavelength 900 nm, detection wavelength 500-550 nm) for optical imaging, and can also inhibit α-synuclein fibril formation by blocking the aggregation process. α-Synuclein aggregate binder 1 can be used for positron emission tomography (PET) imaging after being labeled with 18F. α-Synuclein aggregate binder 1 can be used for visual diagnosis of brain lesions and mechanism research of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia .
Synonyms: E2027
Target:
Research Areas:
Irsenontrine (E2027) is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine can be used for the research of neurological diseases .
Cat. No.: HY-N0698
CAS No.: 55750-84-0
Category:
Neurological Disease Terpenoids Rubiaceae Diterpenoids Plants Gardenia jasminoides Ellis Disease Research Fields Inflammation/Immunology
Target:
Target:
Target:
Cat. No.: HY-113228R
CAS No.: 320-77-4
Synonyms: (Rac)-UCB0599; NPT200-11
Target:
Research Areas:
(Rac)-Minzasolmin ((Rac)-UCB0599; NPT200-11) is a blood-brain barrier penetrated alpha-synuclein (ASYN) misfolding inhibitor. (Rac)-Minzasolmin acts on the early stage of ASYN aggregation process, by replacing the membrane-bound oligomers ASYN, allowing them to revert to the monomeric form, while preventing pathological aggregation. (Rac)-Minzasolmin effectively improves the ASYN deposition in the retina and the neuro-pathological indicators in two α-synuclein transgenic mouse models. (Rac)-Minzasolmin can be used for the studies of Parkinson's disease (PD) and dementia with Lewy bodies (DLB) .
Target:
Research Areas:
PROTAC α-synuclein degrader 3 is a selective α-Synuclein PROTAC degrader. PROTAC α-synuclein degrader 3 promotes ubiquitination and degradation of α-Synuclein. PROTAC α-synuclein degrader 3 can be used in research related to Parkinson's disease and Alzheimer's disease .
Cat. No.: HY-P3140A
Target:
Research Areas:
Target:
Research Areas:
α7 Nicotinic receptor agonist-1 (Preparation 5) is an α7 nAChR agonist. α7 Nicotinic receptor agonist-1 can be used in studies of psychiatric disorders (such as schizophrenia, manic or hypomanic depression and anxiety disorders) and intellectual disorders (such as alzheimer's disease, learning deficits, cognitive deficits, attention deficits, memory loss, lewy body dementia and attention deficit hyperactivity disorder) .
Synonyms: (R)-E2027
Target:
Research Areas:
(R)-Irsenontrine ((R)-E2027), the R-enantiomer of Irsenontrine (HY-132821), is a potent phosphodiesterase 9 (PDE9) inhibitor with an IC50 value of 0.041 μM. (R)-Irsenontrine can be used for the research of neurological diseases .
Cat. No.: HY-178920
CAS No.: 676458-63-2
Target:
Research Areas:
α-Synuclein-IN-17 (Compound 10) is an α-Synuclein inhibitor, with an IC50 value of 9 μM. α-Synuclein-IN-17 exhibits potent inhibitory activity against both in-vitro assembled asyn fibrils and LBD brain tissue-amplified asyn fibrils. α-Synuclein-IN-17 can be used for the study of Parkinson's disease (PD) and Lewy Body Disease (LBD) .
Cat. No.: HY-P3140
CAS No.: 440645-08-9
Target:
Research Areas:
Cat. No.: HY-156634
CAS No.: 2591344-26-0
Synonyms: NYX-783
Target:
Research Areas:
Risevistinel (NYX-783) is a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptor. Nevadistinel can be used to inhibit cognitive impairment associated with neurodegenerative diseases, such as mild cognitive impairment, mild Alzheimer's disease, Parkinson's disease, Lewy body disease .
Cat. No.: HY-175308
CAS No.: 414880-30-1
Target:
Research Areas:
α-Synuclein inhibitor 15 (Compound 1) is an inhibitor targeting the fibrillation growth of α-synuclein (IC50=18 μM). α-Synuclein inhibitor 15 is promising for research of neurodegenerative diseases, such as Parkinson's disease (PD) and Lewy body dementia (LBD) .
Cat. No.: HY-156626
CAS No.: 2181816-92-0
Synonyms: NYX-458; NYX-3054
Target:
Research Areas:
Nevadistinel (NYX-458; NYX-3054) is a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptor. Nevadistinel can be used to inhibit cognitive impairment associated with neurodegenerative diseases, such as mild cognitive impairment, mild Alzheimer's disease, Parkinson's disease, Lewy body disease .
Cat. No.: HY-132821A
CAS No.: 1630083-70-3
Synonyms: E2027 maleate
Target:
Research Areas:
Irsenontrine (E2027) maleate is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine maleate can be used for the research of neurological diseases .
Synonyms: (Rac)-BPN-19186
Target:
Research Areas:
(Rac)-EC5026 ((Rac)-BPN-19186) is a potent piperidine inhibitor of soluble epoxide hydrolase (sEH) extracted from patent WO2019156991A1, page 39, has a Ki of 0.06 nM. (Rac)-EC5026 can be used for the research of Parkinson's disease and dementia with Lewy Bodies (DLB) .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
